Summary & Overview
HCPCS G0219: PET Whole-Body Imaging for Melanoma (Non-Covered Indications)
HCPCS Level II code G0219 denotes whole-body PET imaging performed specifically for melanoma in situations identified as non-covered indications. This code matters nationally because PET imaging plays a central role in staging and surveillance of melanoma, and designation of non-covered use influences billing, appeals, and utilization management across payers. Key payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the code’s clinical intent and common sites of service, an overview of how major payers treat non-covered PET imaging for melanoma, and contextual information on coding and billing implications. The publication highlights benchmarks and policy-related considerations relevant to coverage determination, common modifier usage patterns (where available), and operational impacts for imaging centers and hospital outpatient departments. It also outlines typical clinical scenarios that prompt use of whole-body PET for melanoma and notes where input data was not provided. This resource is intended for revenue cycle professionals, medical coders, and policy analysts seeking a national-level briefing on billing and coverage considerations tied to G0219.
Billing Code Overview
HCPCS Level II code G0219 describes PET imaging, whole body, for melanoma when performed for non-covered indications. The service type is diagnostic whole-body PET imaging used to evaluate the extent of melanoma outside of covered indications. The typical site of service for this procedure is an outpatient imaging center or hospital outpatient department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a history of cutaneous melanoma who presents for systemic staging or evaluation of suspected metastatic disease. The referring dermatologist or oncologist orders a whole-body PET imaging study specific for melanoma imaging when there is clinical concern for regional or distant metastases based on new symptoms (pain, unexplained weight loss), rising serum tumor markers, or suspicious findings on physical exam or other imaging (CT or MRI). The service is performed in an outpatient imaging center or hospital radiology/nuclear medicine department staffed by a nuclear medicine physician and technologists. The workflow includes preauthorization review (often required for PET scans), patient screening for pregnancy and diabetes, radiotracer administration (commonly FDG), appropriate uptake time, whole-body image acquisition, image processing, and interpretation by a board-certified nuclear medicine physician or radiologist. For the particular billing code G0219, this PET whole-body melanoma study is billed when performed for non-covered indications where local payer policy requires reporting of the non-covered service, or when an encounter documents a melanoma-directed PET performed outside standard covered indications. Documentation must include the clinical indication, prior authorization status if obtained, the radiotracer, injected activity, uptake time, technical factors, and a signed interpretation report detailing findings and impression.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |